Apterna

Executive Summary

Apterna is a UK-based precision RNA therapeutics company focused on improving liver function in patients with advanced liver disease. The company's initial target population is patients with compromised liver reserve, which often limits their access to potentially curative therapies. By employing RNA-based modalities, Apterna aims to restore hepatic function and enable these patients to benefit from existing treatments or become eligible for transplantation. Founded in 2019 and headquartered in London, the company is privately held with no disclosed funding rounds or clinical pipelines. Its approach addresses a significant unmet need, as advanced liver disease represents a growing global health burden with limited therapeutic options. Apterna's technology platform leverages precision RNA targeting to selectively modulate gene expression in liver cells, potentially offering a safer and more efficacious alternative to conventional therapies. While the company remains in early preclinical or discovery stages, its focus on a well-defined patient population and a validated biological target positions it for future development. The success of Apterna hinges on demonstrating proof-of-concept in preclinical models and securing financing to advance toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026Lead candidate nomination and IND-enabling studies initiation40% success
• Q3 2026Series A financing round close50% success
• Q2 2026Preclinical efficacy data publication or presentation60% success